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Identifying well-tolerated, oralmedications that enhance adult neurogenesis is of great clinical interest. In this
issue of Cell Stem Cell, Wang et al. (2012) demonstrate that the diabetes medication metformin enhances
spatial learning in mice by activating the atypical PKC/CBP pathway in adult neural stem cells.For organs and tissues that maintain stem
cells throughout life, one strategy for
the treatment of injury or disease is to
enhance the therapeutic potential of
such endogenous stem cell populations.
The adult hippocampus—a brain struc-
ture critical for learning and memory—
harbors a population of neural stem
cells (NSCs) that produce new neurons
throughout life (Ming and Song, 2011),
and this adult neurogenesis is important
for certain forms of memory (Deng et al.,
2010). Adult brain NSCs respond to a
wide range of neurological disorders,
including stroke, seizure, and Alzheimer’s
disease; thus, the prospect of enhancing
their regenerative potential is tantalizing
(Emsley et al., 2005). In this issue of Cell
Stem Cell, Miller and colleagues (Wang
et al., 2012) make advances in this trans-
lational direction with their study of
metformin, a commonly used diabetes
medication, describing its proneurogenic
effects on NSCs and enhancement of one
form of hippocampal-dependent memory
in mice.
Metformin was first synthesized in the
1920s; however, it was not until 1957
that its use for the treatment of diabetes
was clinically appreciated. Metformin
ameliorates high blood sugar without
stimulating insulin secretion or causing
low blood sugar levels, and its long history
of efficacy and safety have made this
small molecule drug the most commonly
prescribed medication for type II diabetes
worldwide. Though its therapeuticmecha-
nisms have not been fully elucidated, met-
formin activates AMP-activated kinase
(AMPK), which reduces the production of
glucose in the liver. In hepatocytes,metformin-activated AMPK phosphory-
lates atypical protein kinase C (aPKC),
which stimulates phosphorylation of
CREB binding protein (CBP), resulting
in decreased gene expression for he-
patic gluconeogenesis (He et al., 2009;
Figure 1A).
CBP is a ubiquitously expressed his-
tone acetyltransferase and transcrip-
tional coactivator. Recently, Miller and
colleagues studied the role of CBP in the
developing murine cortex, showing that
CBP haploinsufficiency results in cogni-
tive deficits (Wang et al., 2010). Given
that phosphorylation of CBP by aPKC
isoform z (aPKCz) is required for CBP-
mediated differentiation of cortical pre-
cursors, the authors hypothesized that
metformin might activate aPKCs in NSCs
as well, thereby increasing neurogenesis.
In their report, Wang et al. first demon-
strate that the aPKC-CBP pathway regu-
lates neuronal differentiation from embry-
onic neural precursor cells. While shRNA
knockdown of either aPKCz or aPKCi
isoforms reduced the number of bIII-
tubulin-positive neurons, cotransfection
of a plasmid encoding an activated form
of CBP with a phosphomimic mutation
(serine to aspartic acid) at the aPKC site
rescued aPKCz knockdown, but not
aPKCi knockdown. Taken together, these
data suggest that CBP is downstream of
aPKCz (Figure 1B).
Next, the authors investigated whether
metformin can activate the aPKC-CBP
pathway in NSCs and promote neurogen-
esis. aPKC phosphorylation at threonine
403 is important for its kinase activity,
and metformin treatment appeared to
modestly increase this modification ofCell StemaPKC in NSCs. More importantly, met-
formin increased the number of bIII-
tubulin-positive cells in culture by up to
50% while decreasing the proportion of
Pax6- and Sox2-positive precursor cells.
This proneurogenic effect was blocked
by aPKCz/i shRNAs as well as CBP
siRNA. When administered to wild-type
adult mice, metformin increased the num-
ber of neurons generated from NSCs in
the dentate gyrus of the hippocampus;
however, when administered to mice
haploinsufficient for CBP, metformin did
not stimulate neurogenesis, suggesting
that this effect of metformin is CBP
dependent.
Intriguingly, Wang et al. show that met-
formin also improves the ability to update
new spatial memories, a task related to
hippocampal neurogenesis (Deng et al.,
2010). Mice were given daily metformin
injections for 38 days and were evaluated
in the Morris water maze to assess their
learning and spatial memory (Fig-
ure 1C). Metformin-treated and control
mice learned and remembered the initial
position of a submerged platform in the
water maze equally well. When the plat-
form was moved to the opposite quad-
rant, both groups were also able to learn
the second position with equal profi-
ciency. When the platform was removed,
however, metformin-treated mice spent
more time in the second quadrant com-
pared to controls, indicating that they
were better able to remember the second
platform position. This finding suggests
that metformin enhanced the ability of
mice to update their spatial memory. In
mice treated with temozolomide, a potent
DNA alkylating agent that kills dividingCell 11, July 6, 2012 ª2012 Elsevier Inc. 5
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Figure 1. Metformin Induces Neurogenesis via CBP Activation and
Enhances Spatial Memory
Metformin is a commonly prescribed oral medication for type II diabetes and
activates AMP-kinase (AMPK). In hepatocytes, activation of AMPK results in
phophorylation of activated protein kinase C (aPKC), which in turn phosphor-
ylates CREB-binding protein (CBP), leading to decreased production of
glucose from the liver (A). In embryonic precursor cells, metformin activates
aPKC isoform z (aPKCz) to enhance neuronal differentiation with CBP serving
as a downstream effector (B). This occurs presumably through metformin’s
effect on AMPK. Administration of metformin also results in improved spatial
memory as tested in the Morris water maze. Mice were treated with metformin
for 38 days during which time they were trained to find a submerged platform
(C, initial phase). The platform was then moved to the opposite quadrant (C,
reversal phase) and the mice were once again trained to find it. There were
no differences among metformin-treated and control groups in these testing
phases. Finally, the platform was removed and the amount of time mice spent
within each quadrant was recorded (C, probe trial). Metformin-treated mice
spent a proportionately larger amount of time in the quadrant that contained
the platform during the reversal phase while control mice spent more time in
the opposite quadrant, suggesting that metformin enhances the ability to
update spatial memory. Abbreviations: Met, metformin; P, phosphorylation.
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duced, and metformin ad-
ministration did not enhance
spatial memory.
Although our understand-
ing of the functional role of
adult neurogenesis is limited,
the notion of modulating this
endogenous process with
oral medications for the
treatment of neurological dis-
orders has garnered much
interest. McKnight and col-
leagues recently screened
1,000 small molecules for
in vivo enhancement of mu-
rine dentate gyrus neuro-
genesis and identified one
candidate, P7C3, with signifi-
cant efficacy and favorable
pharmacological properties
(Pieper et al., 2010). It would
be interesting to compare the
therapeutic efficacy of met-
formin with that of P7C3 in
animal models of Alzheimer’s
disease, aging, and other
neurological disorders. Com-
pared to a novel compound
such as P7C3, clinical trials
with metformin would be re-
latively easy to establish, as
this diabetes medication has
been FDA-approved since
1995. Such repurposing of
drugs has recently been an-
nounced as a major initia-
tive by the National Center
for Advancing Translational
Sciences because it providesa speedy and relatively low-cost strategy
for developing new therapies to treat
human disease.
How else might metformin enhance
spatial learning and have therapeutic
potential for the treatment of cognitive
problems? While the data in this report
support amechanism that involves hippo-
campal neurogenesis, it is also possible
that other mechanisms contribute. For
instance, activated AMPK increases glu-
cose uptake by neurons (Amato and
Man, 2011); thus, metformin may affect
neural metabolism more globally. CBP is
a histone acetyltransferase, and as such,6 Cell Stem Cell 11, July 6, 2012 ª2012 Elsevits activation by metformin may facili-
tate memory formation via synapse
plasticity in a manner similar to the
clinically approved histone deacetylase
(HDAC) inhibitor suberoylanilide hydroxa-
mic acid (SAHA). Intriguingly, SAHA
rescues certainmemory deficits observed
in CBP haploinsufficient mice (Alarco´n
et al., 2004). Furthermore, HDAC inhibi-
tors enhance neurogenesis from adult
NSC populations (Hsieh et al., 2004).
Perhaps metformin in combination with
SAHA will have additive or even syner-
gistic effects on hippocampal-dependent
learning.ier Inc.These studies by Wang
et al. demonstrate that drug
repurposing may be an effec-
tive strategy for translational
research aimed at treating
diseases of the brain. There
are relatively few drugs devel-
oped specifically for neu-
rological conditions and even
fewer engineered for stem-
cell-based regenerative med-
icine. Perhaps it will be well
worth opening up the medi-
cine cabinet of the past
to look for unexpected cel-
lular effects and potential
therapeutic benefits using
the modern tools and les-
sons learned from stem cell
biology.
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